HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lead Compounds “Reasonably Anticipated” To Be Carcinogenic – NTP Panel

This article was originally published in The Rose Sheet

Executive Summary

Lead and all lead compounds should be included in the 11th Report on Carcinogens, a National Toxicology Program Board of Scientific Counselors RoC subcommittee concluded at an Oct. 14 meeting in Washington, D.C

You may also be interested in...



NTP Report Finds DAAB Is “Reasonably Anticipated” Carcinogen

Diazoaminobenzene is "reasonably anticipated to be a human carcinogen" based on studies demonstrating it is metabolized to benzene, a "known human carcinogen," according to the National Toxicology Program's 11th Report on Carcinogens

NTP Report Finds DAAB Is “Reasonably Anticipated” Carcinogen

Diazoaminobenzene is "reasonably anticipated to be a human carcinogen" based on studies demonstrating it is metabolized to benzene, a "known human carcinogen," according to the National Toxicology Program's 11th Report on Carcinogens

NTP lead review

National Toxicology Program requests final public comments on seven nominees for listing in the 11th Report on Carcinogens, including lead, which is found in some "traditional" cosmetics, according to the agency. Comments will be accepted for 60 days from publication of Nov. 6 Federal Register 1notice announcing solicitation. NTP's Board of Scientific Counselors RoC Subcommittee voted to list lead as "reasonably anticipated to be a human carcinogen" Oct. 14 (2"The Rose Sheet" Oct. 20, 2003, p. 8)...

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel